Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02790073 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study With SNF472 in Calciphylaxis Patients
A Phase 2 study, sponsored by Sanifit Therapeutics S. A..
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT02790073: Completed Phase 2 study, sponsored by Sanifit Therapeutics S. A..
NCT02790073 is a Phase 2 study that has completed, run by Sanifit Therapeutics S. A.. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02790073, a Phase 2 study, has completed, sponsored by Sanifit Therapeutics S. A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
Primary Outcome
Absolute change in Bates-Jensen Wound Assessment (BWAT) total score between baseline (Week 1) and Week 12 for the primary lesion (the largest one). The Bates-Jensen Wound Assessment (BWAT) is a standardized tool for quantitative assessment of wound healing that includes the 13 items listed below. * Size * Depth * Edges * Undermining or pockets * Necrotic tissue type * Necrotic tissue amount * Exudate type * Exudate amount * Surrounding skin color * Peripheral tissue edema * Peripheral tissue i
Interventions
- DRUG SNF472
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 2 |
What the finished NCT02790073 record still lists
NCT02790073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which SNF472 is the first listed.
NCT02790073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02790073 about?
NCT02790073 is a clinical study titled "Phase 2 Study With SNF472 in Calciphylaxis Patients". To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
What is the current status of trial NCT02790073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2016-05. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT02790073?
The interventions under investigation include: SNF472 (DRUG).
Who is sponsoring clinical trial NCT02790073?
This trial is sponsored by Sanifit Therapeutics S. A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02790073's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia